



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Datasheet for 009-001-R59S**CBP protein-GST fusion****Overview**

| | |
|----------------------|---|
| Description: | CBP recombinant protein-GST fusion protein - 009-001-R59S |
| Item No.: | 009-001-R59S |
| Size: | 20 µg |
| Origin: | Human |
| Expressed in: | E. coli |

Product Details

Background: CBP or CREB-binding protein is a nuclear transcriptional coactivator protein that binds specifically to the PKA-phosphorylated form of the CREB protein. Microinjection of an anti-CBP antiserum into fibroblasts leads to inhibition of transcription from a cAMP promoter (1). CBP can also cooperate with upstream activators, such as JUN. When JUN is phosphorylated at the transcriptionally stimulatory sites ser73 and ser63, it binds CBP with comparable affinity to CREB. Insulin signaling may directly regulate many cAMP signaling pathways at the transcriptional level by controlling CBP recruitment (2). Mutant CBP can be aberrantly recruited to CREB protein, resulting in inappropriate activation of gluconeogenesis and glucose intolerance. CBP Protein is ideal for investigators involved in Signaling Proteins, Transcription Proteins, Apoptosis/Autophagy, Cardiovascular Disease, ERK/MAPK Pathway, Inflammation, Invasion/Metastasis, Metabolic Disorder, Neurobiology, NfκB Pathway, and PKA/PKC Pathway research.

| | |
|---------------------------|--|
| Synonyms: | CREB Binding Protein, CREBBP, RTS, RSTS, CBP |
| Species of Origin: | Human |
| Expressed in: | E. coli |
| Type: | Recombinant Protein |

Target Details

| | |
|----------------------------|--|
| Gene Name: | CREBBP |
| Purity/Specificity: | Recombinant human CBP (1319-1710) was expressed in E. coli cells using an N-Terminal Glutathione-S-Transferase fusion protein. The purity was determined to be >90% by densitometry. |

Relevant Links: • [NCBI - NM_004380](#)

Application Details

Application Note: CBP Protein is stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. CBP Protein is suitable for use in Western Blot. Expect a band approximately ~ 71kDa on specific lysates or tissues. Specific conditions for reactivity should be optimized by the end user.

Assay Dilutions: All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

WB: User Optimized

Formulation

Physical State: Liquid (sterile filtered)

Concentration: 0.2 µg/µL

Buffer: See application note.

Shipping & Handling

Shipping Condition: Dry Ice

Storage Condition: Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Expiration: Expiration date is one (1) year from date of receipt.

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

